Darunavir: A Critical Review of Its Properties, Use and Drug Interactions
dc.contributor.author | Ruela Correa, Josilene Chaves [UNESP] | |
dc.contributor.author | D'Arcy, Deirdre M. | |
dc.contributor.author | dos Reis Serra, Cristina Helena | |
dc.contributor.author | Salgado, Hérida Regina Nunes [UNESP] | |
dc.contributor.institution | Universidade Estadual Paulista (Unesp) | |
dc.contributor.institution | Universidade de São Paulo (USP) | |
dc.contributor.institution | Trinity Coll Dublin | |
dc.date.accessioned | 2014-05-20T13:24:55Z | |
dc.date.available | 2014-05-20T13:24:55Z | |
dc.date.issued | 2012-01-01 | |
dc.description.abstract | Darunavir is a synthetic nonpeptidic protease inhibitor which has been shown to be extremely potent against wildtype HIV as well as a large panel of PI-resistant clinical isolates and shows a high genetic barrier to the development of antiretroviral resistance. The treatment of HIV/AIDS requires combinations of multiple antiretroviral drugs. In addition, patients frequently need to coadminister other medications for reasons including the prevention or treatment of opportunistic infections, treatment of concomitant illnesses and management of antiretroviral side effects. Drug interactions have been observed between darunavir and other drugs. New and more comprehensive drug interaction studies will be required since the increase in life expectancy of patients often brings new comorbidities and the concomitant use of different drugs. This paper discusses the impact of the use of darunavir in the treatment of HIV-infected patients, its pharmacological and physical-chemical properties, its drug interactions, and challenges that remain in order to ensure safety and compliance of treatment. Copyright (C) 2012 S. Karger AG, Basel | en |
dc.description.affiliation | Univ Estadual Paulista, Sch Pharmaceut Sci, Drugs & Med Qual Control Lab, BR-14801902 Araraquara, Brazil | |
dc.description.affiliation | Univ São Paulo, Sch Pharmaceut Sci, São Paulo, Brazil | |
dc.description.affiliation | Trinity Coll Dublin, Sch Pharm & Pharmaceut Sci, Dublin, Ireland | |
dc.description.affiliationUnesp | Univ Estadual Paulista, Sch Pharmaceut Sci, Drugs & Med Qual Control Lab, BR-14801902 Araraquara, Brazil | |
dc.description.sponsorship | Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) | |
dc.description.sponsorship | Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) | |
dc.description.sponsorship | Fundação para o Desenvolvimento da UNESP (FUNDUNESP) | |
dc.description.sponsorship | PADC-UNESP | |
dc.format.extent | 102-109 | |
dc.identifier | http://dx.doi.org/10.1159/000339862 | |
dc.identifier.citation | Pharmacology. Basel: Karger, v. 90, n. 1-2, p. 102-109, 2012. | |
dc.identifier.doi | 10.1159/000339862 | |
dc.identifier.issn | 0031-7012 | |
dc.identifier.uri | http://hdl.handle.net/11449/7862 | |
dc.identifier.wos | WOS:000307156100011 | |
dc.language.iso | eng | |
dc.publisher | Karger | |
dc.relation.ispartof | Pharmacology | |
dc.relation.ispartofjcr | 1.538 | |
dc.relation.ispartofsjr | 0,502 | |
dc.rights.accessRights | Acesso aberto | |
dc.source | Web of Science | |
dc.subject | Darunavir | en |
dc.subject | Human immunodeficiency virus | en |
dc.subject | Acquired immune deficiency syndrome | en |
dc.subject | Clinical pharmacokinetics | en |
dc.subject | Drug interactions | en |
dc.subject | Biopharmaceutics classification system | en |
dc.title | Darunavir: A Critical Review of Its Properties, Use and Drug Interactions | en |
dc.type | Artigo | |
dcterms.license | http://www.karger.com/Journal/Guidelines/238704#15 | |
dcterms.rightsHolder | Karger | |
unesp.campus | Universidade Estadual Paulista (Unesp), Faculdade de Ciências Farmacêuticas, Araraquara | pt |
unesp.department | Fármacos e Medicamentos - FCF | pt |
Arquivos
Licença do Pacote
1 - 2 de 2
Nenhuma Miniatura disponível
- Nome:
- license.txt
- Tamanho:
- 1.71 KB
- Formato:
- Item-specific license agreed upon to submission
- Descrição:
Nenhuma Miniatura disponível
- Nome:
- license.txt
- Tamanho:
- 1.71 KB
- Formato:
- Item-specific license agreed upon to submission
- Descrição: